Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU TopicsInfection / pharmacology

ICU · Infection / pharmacology

Beta-Lactam Antibiotics — Penicillins, Cephalosporins, Carbapenems, Monobactams

Also known as Beta-lactam · Penicillin · Cephalosporin · Carbapenem · Meropenem · Piperacillin-tazobactam · Flucloxacillin · Ceftriaxone · Ceftazidime · Cefepime · Ceftaroline · Aztreonam · Beta-lactamase inhibitor · Prolonged infusion

The beta-lactam antibiotics share the beta-lactam ring and the mechanism — the bind the PBPs, the inhibit the cell-wall (the peptidoglycan) synthesis, the bactericidal, the time-dependent (the T over the MIC drives the prolonged or the continuous infusion in the severe sepsis). The four subclasses: the penicillins (the piperacillin-tazobactam the broad and the pseudomonal, the flucloxacillin the staph MSSA not MRSA, the amoxiclav), the cephalosporins (the ceftriaxone or the cefotaxime the 3rd no pseudomonal, the ceftazidime the 3rd pseudomonal, the cefepime the 4th pseudomonal, the ceftaroline the 5th MRSA), the carbapenems (the meropenem the broadest — the ESBL — the reserve for the MDR, the imipenem the seizures), and the monobactams (the aztreonam the Gram-negative only, the safe in the penicillin allergy). The resistance: the beta-lactamases (the solved by the clavulanate or the tazobactam or the avibactam), the altered PBPs (the MRSA PBP2a — needs the vancomycin). The adverse: the allergy (the low cross-reactivity), the C. difficile, the interstitial nephritis, the seizures (the high-dose or the imipenem).

high38 referencesUpdated 17 Aug 202636 min readSource-verified · Sept 2026

Checked against its sources on 2 Sept 2026

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC
The one-paragraph exam answer

The beta-lactams are structural analogues of the D-Ala-D-Ala terminus — they covalently acylate the penicillin-binding proteins, wreck peptidoglycan cross-linking, and kill by time-dependent cell lysis, so efficacy tracks the time the free-drug concentration stays above the MIC (T above MIC), not the peak. That single pharmacodynamic law is why we prolong or continuously infuse them in severe sepsis — though the BLING III trial of ~7000 patients found no routine mortality benefit. Four subclasses share the ring: penicillins (flucloxacillin is MSSA-only and never MRSA; piperacillin-tazobactam is the ICU workhorse but fails ESBL bacteraemia by the MERINO rule), cephalosporins (ceftriaxone has no Pseudomonas cover; ceftazidime is the only third-generation that does; cefepime is AmpC-stable but neurotoxic in renal failure; ceftaroline is the only beta-lactam active against MRSA), carbapenems (meropenem is the broadest and the ESBL drug; imipenem seizes; ertapenem spares Pseudomonas), and monobactams (aztreonam is Gram-negative-only and the safe bet in penicillin anaphylaxis — except it shares a side-chain with ceftazidime). Match the beta-lactamase to its inhibitor: ESBL and AmpC to cefepime or a carbapenem; KPC to ceftazidime-avibactam; and NDM is NOT avibactam — add aztreonam.[1]

Meet the patient

A 68-year-old man is admitted overnight, eight days out from a partial colectomy, with rigors, confusion and a lactate of 4.6 mmol/L. He is in septic shock on noradrenaline 0.35 mcg/kg/min, the chest X-ray shows a right lower-lobe infiltrate, and an indwelling catheter has been in for five days. The question you must answer in the first hour is the question this whole topic turns on: what empiric beta-lactam is broad enough for a nosocomial, possibly ESBL-producing source — and what will you switch to when the cultures come back?[4]

Hold that patient in mind. Every subclass, every trap, and every trial below answers one piece of his care — the empiric choice (piperacillin-tazobactam or cefepime plus vancomycin), the MERINO-driven de-escalation if his blood cultures grow an ESBL Klebsiella, and the day-three decision to stop antibiotic moment the source is controlled.[4]

ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References38ShowHide
  1. [1]Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Paterson DL A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis Am J Respir Crit Care Med, 2015.PMID 26200166
  2. [2]Dulhunty JM, Brett SJ, De Waele JJ, et al. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial JAMA, 2024.PMID 38864155
  3. [3]Abdul-Aziz MH, Hammond NE, Brett SJ, et al. Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic Shock: A Systematic Review and Meta-Analysis JAMA, 2024.PMID 38864162
  4. [4]Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial JAMA, 2018.PMID 30208454
  5. [5]Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections Clin Infect Dis, 2024.PMID 39108079
  6. [6]McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) Clin Infect Dis, 2018.PMID 29462280
  7. [7]Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial Lancet Infect Dis, 2019.PMID 31563344
  8. [8]Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial Lancet Infect Dis, 2018.PMID 29254862
  9. [9]Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections Clin Infect Dis, 2020.PMID 31400759
  10. [10]Picard M, Robitaille G, Karam F, et al. Cross-Reactivity to Cephalosporins and Carbapenems in Penicillin-Allergic Patients: Two Systematic Reviews and Meta-Analyses J Allergy Clin Immunol Pract, 2019.PMID 31170539
  11. [11]Hagel S, Bach F, Brenner T, et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial Intensive Care Med, 2022.PMID 35106617
  12. [12]Abdul-Aziz MH, Portunato F, Roberts JA Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base Curr Opin Infect Dis, 2020.PMID 33009140
  13. [13]Li J, Echevarria KL, Traugott KA β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins Pharmacotherapy, 2017.PMID 28035690
  14. [14]Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group Benzylpenicillin versus flucloxacillin or cloxacillin for the treatment of penicillin-susceptible Staphylococcus aureus bacteraemia (SNAP): an international, multicentre, open-label, non-inferiority randomised controlled trial Lancet, 2026.PMID 42309115
  15. [15]Meenks SD, Punt N, le Noble JLML, et al. Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study Crit Care, 2023.PMID 36869388
  16. [16]Luther MK, Timbrook TT, Caffrey AR, et al. Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis Crit Care Med, 2018.PMID 29088001
  17. [17]Bamberg M, Menger MM, Thiel JT, et al. Antibiotics in patients with severe burn injury-A modifiable variable in hypernatremia etiology Injury, 2024.PMID 38679560
  18. [18]Norrby SR Neurotoxicity of carbapenem antibacterials Drug Saf, 1996.PMID 8884160
  19. [19]Xu ZR, Ran XW, Xian Y, et al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial J Antimicrob Chemother, 2016.PMID 26888908
  20. [20]Seo YB, Lee J, Kim YK, et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli BMC Infect Dis, 2017.PMID 28592240
  21. [21]Xu H, Zhou W, Zhou D, et al. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis J Clin Pharmacol, 2017.PMID 27530649
  22. [22]Caruso C, Valluzzi RL, Colantuono S, et al. β-Lactam Allergy and Cross-Reactivity: A Clinician's Guide to Selecting an Alternative Antibiotic J Asthma Allergy, 2021.PMID 33500632
  23. [23]Tan JJ, Zhou PY, Chua NGS, et al. The Safety of Aztreonam Versus Ceftazidime in Patients Labeled With Penicillin Allergy: A Cohort Study Clin Ther, 2024.PMID 38942719
  24. [24]Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection N Engl J Med, 2011.PMID 21288078
  25. [25]Scheetz MH, McKoy JM, Parada JP, et al. Systematic review of piperacillin-induced neutropenia Drug Saf, 2007.PMID 17408306
  26. [26]Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, et al. Augmented Renal Clearance in Critically Ill Patients: A Systematic Review Clin Pharmacokinet, 2018.PMID 29441476
  27. [27]McKenzie C Antibiotic dosing in critical illness J Antimicrob Chemother, 2011.PMID 21398304
  28. [28]Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR) Crit Care, 2019.PMID 30925922
  29. [29]Beijer G, Swartling M, Nielsen EI, et al. First dose target attainment with extended infusion regimens of piperacillin and meropenem Crit Care, 2025.PMID 40405288
  30. [30]Taniguchi J, Aso S, Matsui H, et al. Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study J Antimicrob Chemother, 2025.PMID 40492536
  31. [31]Muraro A, Worm M, Alviani C, et al. EAACI guidelines: Anaphylaxis (2021 update) Allergy, 2022.PMID 34343358
  32. [32]Rybak MJ, Le J, Lodise TP, et al. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists Pharmacotherapy, 2020.PMID 32227354
  33. [33]Heo YA Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections Drugs, 2021.PMID 33630278
  34. [34]Karaiskos I, Gkoufa A, Kyriazopoulou E An update on beta-lactam-beta-lactamase inhibitor combinations for the treatment of carbapenem-resistant Gram-negative pathogens Expert Opin Drug Metab Toxicol, 2026.PMID 42317028
  35. [35]Genovese C, Colaneri M, Sguazzini E Pharmacokinetic and pharmacokinetic/pharmacodynamic (PK/PD) considerations of ceftaroline and ceftobiprole for the treatment of Staphylococcus aureus infections: a systematic review Int J Antimicrob Agents, 2026.PMID 42575220
  36. [36]Keerthi V, Ravindran P, Kaliyur S A comprehensive review of emerging therapeutic strategies against methicillin-resistant Staphylococcus aureus Front Microbiol, 2026.PMID 42614264
  37. [37]Kumar D, Kaur N, Surender Nacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens Ann Med Surg (Lond), 2026.PMID 42254231
  38. [38]Zobell JT, Waters CD, Young DC Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins Pediatr Pulmonol, 2013.PMID 22949297

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAntivirals — Aciclovir, Oseltamivir & the Anti-COVID AgentsInfection / pharmacologyNextGlycopeptides & Lipopeptides — Vancomycin, Teicoplanin, DaptomycinInfection / pharmacology